-
November 22, 2024 Lupin’s ESG Score Rises to 76 in S&P Global ESG Ratings
-
November 20, 2024 Lupin and NAPCON Hosts a Walkathon ‘A Step Towards HealThy Lungs’ for COPD Awareness
-
November 19, 2024 Lupin Launches Bumetanide Injection, USP in the United States
-
November 19, 2024 Lupin Receives Approval from U.S. FDA for Mixed Salts of a Single-Entity Amphetamine Extended-Release Capsules
-
November 18, 2024 Lupin’s Humrahi Diabetes Support Program Expands to Include Heart Health
-
November 8, 2024 Lupin Receives Tentative Approval from U.S. FDA for Raltegravir Tablets, USP
-
November 7, 2024 Lupin Q2 FY2025 Results
-
October 28, 2024 Lupin to focus on the development of inhalers with near-zero global warming potential propellants
-
October 21, 2024 Lupin Appoints Claus Jepsen as President, Global Specialty
In this section
Media Contacts
-
Rajalakshmi Azariah
Vice President & Global Head – Corporate Communications